Home » News » Covid-19

News and releases

Covid-19

Categories
14. March 2022

ISIDORe – “Integrated Services for Infectious Disease Outbreak Research” – officially launched

ISIDORe - “Integrated Services for Infectious Disease Outbreak Research”, has been officially launched on 24 February 2022. This 21M€ EU-funded large-scale project assembles an unprecedented One Health-driven, integrated portfolio of cutting-edge research services and resources, dedicated to the study of epidemic-prone diseases including SARS-CoV-2 variants. VFI offers a range of TransNational Access Services on adjuvants and formulation expertise in order to fight epidemic diseases.

For Press release read here

16. November 2021

CEPI awards VIDO and VFI for COVID-19 variants vaccine development

VFI is pleased to announce its continued partnership with VIDO, thanks to a 5M USD award from CEPI (Coalition of Epidemics Preparedness Innovations), to develop new vaccines that are broadly protective against COVID-19 variants and suitable for use in Low- and Middle-Income Countries. This work builds on the development of COVAC-2, VIDO’s subunit vaccine formulated with Sepivac SWE™, an adjuvant co-developed by Seppic and VFI.

Click here to read VIDO press release and CEPI press release

28. June 2021

USask’s VIDO announces positive Phase 1 results for COVAC-2

 

VFI is pleased to share news on positive Phase 1 results for COVAC-2, a COVID-19 subunit vaccine candidate developed by Usask's VIDO, formulated with Sepivac SWE™️, an adjuvant developed by VFI and Seppic. Click here to read the press release.

 

05. February 2021

Start of COVAC-2 phase 1 clinical trial

Start of COVAC-2 phase 1 clinical trial! A COVID-19 vaccine developed by VIDO which includes the open-access adjuvant Sepivac SWE, co-developed by VFI and Seppic.

Read press release

07. January 2021

VIDO’s COVID-19 vaccine receives Health Canada clinical trial approval

VIDO’s COVID-19 vaccine receives Health Canada clinical trial approval for subunit-based vaccine combined to the open-access adjuvant Sepivac SWE, that was developed by Seppic in collaboration with VFI. First-in-human trials are planned in January 2021.

Read press release

04. December 2020

The Vaccine Formulation Institute’s squalene-in-water adjuvant SWE is now available from our partner Seppic under the name Sepivac SWE™

Sepivac SWE™ is prepared at cGMP-grade and is being made available to the entire vaccine community under open-access terms. Sepivac SWE™ adjuvant can be used in the composition of several vaccines including vaccines against seasonal influenza, pandemic influenza and COVID-19. A production capacity of several hundred million doses per year of Sepivac SWE™ is expected by summer 2021.

VFI is proud to have co-led the development of the first open-access adjuvant for prophylactic use since aluminium salts in the 1920’s and is grateful to its initial funders (European Commission, US-HHS BARDA and GIZ) for having catalysed the development of the SWE adjuvant. We look forward to continuing this long-term partnership with our Seppic colleagues.

Read Seppic press release

12. November 2020

VFI’s fight against Coronavirus during 2nd wave of COVID pandemic

With fitting measures, VFI laboratories will remain operational during the second wave of COVID-19 pandemic. We continue our vaccine development efforts in collaboration with the Bill & Melinda Gates Foundation and other partners in order to develop rapid solutions against the pandemic.

27. April 2020

VFI and Seppic announce co-development of a GMP emulsion-based adjuvant for human prophylactic vaccines (including COVID-19 vaccines) on an open-access basis

VFI and Seppic announced that they have finalized the development of an oil-in-water adjuvant at a Seppic plant in France. The adjuvant, manufactured under Good Manufactured Practices, will be openly available from Seppic before the end of this year, for the entire vaccine community.

Read press release

17. March 2020

VFI supports Sars-Cov-2 vaccine development through TRANSVAC2 (European Commission)

As partner of TRANSVAC2, VFI offers its adjuvant and formulation services to vaccine researchers and developers in the context of Covid-19. Vaccine researchers and developers can ship their Sars-Cov-2 vaccine antigens to VFI for formulation with adjuvants suitable for clinical use. Once optimal formulations are identified, VFI can perform immunogenicity studies in mice including analyses of B- and T-cell responses. First deadline for application is 15 April 2020.

01. March 2020

VFI supports Sars-Cov-2 vaccine development through GH-VAP (Bill & Melinda Gates Foundation)

VFI is working with grantees from the Bill & Melinda Gates Foundation (BMGF) to evaluate Sars-Cov-2 vaccine candidates. Antigens provided by BMGF grantees are appropriately formulated with adjuvants developed by VFI with the ultimate goal to identify suitable Sars-Cov-2 vaccine candidates which can progress towards the clinic. This work is supported by the Global Health Vaccine Accelerator Platforms (GH-VAP) funded by BMGF.

17. February 2020

VFI will actively support the development of vaccines against Covid-19

VFI will support the vaccine community during Covid-19 pandemic. VFI is currently manufacturing several adjuvants to be included in upcoming Covid-19 studies and has secured access to animal facilities for immunogenicity studies of adjuvanted-Sars-Cov-2 vaccine formulations. VFI is also setting up collaborations with numerous vaccine developers worldwide in order to formulate Sars-Cov-2 vaccine candidates with VFI adjuvants to induce relevant immune responses.

VFI headquarters and Geneva laboratories

Rue du Champ-Blanchod 4
1228 Plan-les-Ouates
Switzerland

VFI Lausanne laboratories

Route de la Corniche 5
1066 Epalinges
Switzerland

contact@vformulation.org
VFI on LinkedIn

© 2024 Vaccine Formulation Institute